To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 2

VerifiedRx

English - September 20, 2022 14:00 - 13 minutes - 30.5 MB - ★★★★★ - 9 ratings
Medicine Health & Fitness Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 1

Next Episode: The managed care equation: connecting your health plan and your pharmacists

Dr. Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic and Steven Lucio, Senior Principal in Pharmacy Solutions at Vizient discuss their insights on the approval, role, and coverage of Aducanumab, the first drug in a new class approved for Alzheimer’s by the FDA’s accelerated approval process.

Guest speakers:
Mandy Leonard, PharmD, BCPS
Senior Director of Drug Use Policy and Formulary Management
Cleveland Clinic

Steven Lucio, PharmD, BCPS
Senior Principal in Pharmacy Solutions
Vizient

Moderator:
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence

Show Notes:

[00:47 -3:06] Other factors driving aducanumab formulary decision making

[03:07-6:35] How CMS is managing this medication

[06:36-9:04] What should patients and families know about this medication?

[09:05-12:33] What frontline pharmacists should know about this medication

Links | Resources:

To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 1

EMERGE and ENGAGE

American Academy of Neurology statement